Nkarta keeps natural killer therapy ball rolling with plans for new San Francisco headquarters, manufacturing site

Nkarta Therapeutics isn’t slowing down. The biotech made an impressive IPO debut last July and then followed that up by dosing the first patient with its leading off-the-shelf cancer immunotherapy a few months later.